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The explosion of interest in induced pluripotent stem cells has been fueled by their potential as
a limitless source of cells to repair damaged tissues in any number of diseases. However, gener-
ating cells is only a small part of the problem; ensuring that these cells integrate into their new
environment and function appropriately is now a more pressing challenge. In this issue’s Select,
we focus on four recent papers that tackle this problem and find that new ways to stimulate endog-
enous regeneration are providing promising alternatives to restore organ function.Cells isolated from hearts injected with the re-
programming factors. The green cell represents
a pre-existing cardiomyocyte, and the yellow
cells represent newly born induced cardiomyo-
cytes.Reprogramming Goes Native in the Heart
Ischemic heart disease is the leading cause of death globally, and efforts to
repair damaged cardiac tissue have so far met with limited success, in part
because cardiac muscle has an extremely limited intrinsic ability to regenerate.
However, roughly half of the cells in the mammalian heart are fibroblasts. Could
these cells be transdifferentiated to supply the heart with newmuscular tissue?
Direct reprogramming of fibroblasts into cardiomyocytes has been achieved
in vitro, but relatively few fully reprogrammed cells are generated. Srivastava
and colleagues now demonstrate that reprogramming endogenous cardiac
fibroblasts in mice is possible and results in more fully reprogrammed muscle
cells that functionally integrate into the existing myocardium. Three lineage-
specific transcription factor genes (Gata4, Mef2c, and Tbx5) are delivered
into the heart by direct injection of a retrovirus. Under normal circumstances,
cardiac fibroblasts are relatively quiescent, and because stable infection with
retroviruses requires an actively dividing population, relatively few cells aretransduced. However, injuring the heart by ligating a coronary artery, effectivelymimicking a heart attack, stimulates fibroblast
proliferation, and treatment with the retrovirus after such an injury results in substantial levels of infection. The efficiency of
initial reprogramming is comparable to that achieved in vitro, with around 12% of infected cells expressing cardiomyocyte
markers. However, these new cells remarkably contribute to a significant improvement in cardiac function 3 months following
damage. It seems likely that even greater therapeutic outcomeswill be possible if the frequency of reprogramming is improved
and the means of delivery optimized. How long then before reprogramming genes make their way into the emergency room?
Qian, L., et al. (2012). Nature. Published online April 18, 2012. 10.1038/nature11044.Therapies for rheumatoid arthritis are currently
limited to pain management and surgery.Differentiation Drug Reconstructs Cartilage
For cases in which endogenous stem cells are present and intact in the
damaged organ, simply nudging these cells to differentiate into the desired
tissue type may be all that is required. Schultz and coworkers take this
approach, with the aim of repairing damaged cartilage inmousemodels of oste-
oarthritis. Current therapies for this debilitating joint disease are limited to
surgery and pain management. Attempts to slow or reverse disease progres-
sion with drugs have so far focused on protecting cartilage-producing chondro-
cytes from inflammatory damage or inhibiting matrix-degrading enzymes.
However, so far, these approaches have met with limited success. The authors
instead screen a library of 22,000 small molecules for their ability to promote
differentiation of mesenchymal stem cells into chondrocytes in vitro. One mole-
cule, which they named kartogenin, not only stimulates chondrocyte differenti-
ation, but also appears to protect mature chondrocytes from inflammatory
cytokines. When tested in two different osteoarthritis models, kartogenin promotes regeneration of the cartilage matrix
and significantly reduces levels of pain, with no obvious side effects. Using crosslinking, the team identified filamin A as
the cellular target and went on to define the mechanism by which kartogenin stimulates cartilage repair. Interaction with
the drug prevents filamin A from binding and sequestering CBFb, a cofactor of the RUNX family of transcription factors.
Strikingly, 5 of the 39 genes identified in a microarray analysis of gene expression changes induced by kartogenin are known
targets of RUNX1, and knocking down CBFb or RUNX1 prevents kartogenin from stimulating chondrocyte differentiation.
Together, the findings suggest that kartogenin, through its effects on chondrocyte differentiation and survival, may be
a valuable component in a multipronged strategy to combat osteoarthritis.
Johnson, K., et al. (2012). Science. Published online April 5, 2012. 10.1126/science.1215157.Cell 149, May 11, 2012 ª2012 Elsevier Inc. 727
A cascade of cytokines links double-positive
thymocyte number to thymic epithelial regener-
ation.A Cytokine for Immune Recovery
The thymus is endowed with an innate capacity to regenerate, and this property
is critical in patients recovering from treatments involving cytotoxic drugs
or irradiation, such as those undergoing cancer chemotherapy or hematopoi-
etic stem cell transplants. However, in old age, thymic regeneration can be
impaired, leaving elderly patients with a weakened adaptive immune system
and a high risk of infection. Understanding the mechanisms of thymic renewal
may provide vital clues as to how to accelerate this process. Van den Brink and
colleagues identify a cytokine cascade that stimulates proliferation of thymic
epithelial cells. Mice that are unable to produce IL-22 fail to regenerate the
thymus following total body irradiation (TBI), and treatment of irradiated wild-
type mice with IL-22 accelerates thymic recovery. Searching for the source of
IL-22, the authors identify a specialized population of RORg(t)-positive innate
lymphoid cells in the thymus, known as lymphoid tissue inducer cells. Mice
lacking RORg(t) have normal levels of IL-22 under basal conditions but fail to
increase IL-22 production in response to thymic injury. Tracing further back
through the mechanism, the authors show that inducer cells are stimulated
by IL-23 secreted by dendritic cells in the thymus. It remains unclear how this
cascade is triggered by thymic injury, but several results suggest that dendritic
cells respond specifically to the number of CD4+CD8+ double-positive thymo-cytes present. Halting T cell development prior to the double-positive stage promotes IL-22 production; however, a block at
the later single-positive stage has no effect. Levels of IL-22 and IL-23 inversely correlate with the number of double-positive
cells present, and selective killing of double-positive T cells with dexamethasone stimulates IL-22 secretion by innate
lymphoid cells. It remains to be seen how this counting mechanism operates, but the therapeutic implications of the study
are already clear: IL-22 may provide an effective means of boosting thymic regeneration in vulnerable patients.
Dudakov, J.A., et al. (2012). Science 336, 91–95.Integrated rod photoreceptor cells (green)
following subretinal injection of rod photore-
ceptor precursors into an adult mouse.Restoring Sight
Its relative ease of access and immune privileged status have made the retina
one of the most promising targets for cell-based therapies, with phase I clinical
trials of retinal pigment epithelium already well underway for the treatment of an
inherited form of visual impairment. However, the transplantation of photore-
ceptors poses a distinct challenge in that new photoreceptor cells must inte-
grate and form functional synapses with endogenous neurons. A key question
is therefore whether cell transplantation will ever be capable of restoring sight.
Ali and coworkers provide convincing evidence that suggests that we have
every reason to be optimistic. They take advantage of a mouse model of
congenital night blindness in which the retina lacks functional rod cells that
are necessary for vision in low light conditions. By improving their transplanta-
tion protocols, they succeed in transferring 20–30 times more cells than
previous attempts. Although the transplanted neurons are responsive to light,
electroretinograms, which measure the retinal response more globally, fail to
detect any improvement in sensitivity over a period of 6 weeks. Despite this,
low light stimuli generate a robust response in the visual cortex, consistent
with the idea that retinal signals are significantly amplified as they transit
through the visual pathway. Most excitingly, treated mice displayed clear signs
of functional vision in a number of behavioral tests under low light, including awater maze test that requires cognitive process-
ing of visual information. The best-performing animals had the largest number of transplanted cells, with areas of higher
density being particularly important. These findings suggest that recovery of as little as 1% of rod function is sufficient to
restore some degree of functional vision. If further improvements in transplantation efficiency are achievable, the future
may indeed be bright.
Pearson, R.A., et al. (2012). Nature. Published online April 18, 2012. 10.1038/nature10997.
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